Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6UY14
UPID:
ATL4_HUMAN
Alternative names:
Thrombospondin repeat-containing protein 1
Alternative UPACC:
Q6UY14; B2RTT0; F8WAD0; Q5T5F7; Q6IPM6; Q8N643; Q9HBS6
Background:
ADAMTS-like protein 4, also known as Thrombospondin repeat-containing protein 1, plays a crucial role in the positive regulation of apoptosis and may facilitate FBN1 microfibril biogenesis. This protein's involvement in the structural integrity of connective tissues highlights its importance in cellular processes.
Therapeutic significance:
Linked to ocular abnormalities such as Ectopia lentis 2, isolated, autosomal recessive, and Ectopia lentis et pupillae, ADAMTS-like protein 4's genetic variants offer insights into its pathological roles. Understanding the role of ADAMTS-like protein 4 could open doors to potential therapeutic strategies for these eye conditions.